Fmr LLC Sells 592,030 Shares of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)

FMR LLC decreased its position in Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) by 16.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 2,988,126 shares of the biotechnology company’s stock after selling 592,030 shares during the period. FMR LLC owned approximately 4.26% of Progenics Pharmaceuticals worth $28,208,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of PGNX. Teachers Advisors LLC boosted its stake in shares of Progenics Pharmaceuticals by 2.5% in the fourth quarter. Teachers Advisors LLC now owns 111,935 shares of the biotechnology company’s stock worth $967,000 after buying an additional 2,769 shares during the period. American International Group Inc. boosted its stake in shares of Progenics Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 42,864 shares of the biotechnology company’s stock worth $405,000 after buying an additional 2,835 shares during the period. Fox Run Management L.L.C. boosted its stake in shares of Progenics Pharmaceuticals by 64.1% in the first quarter. Fox Run Management L.L.C. now owns 19,532 shares of the biotechnology company’s stock worth $184,000 after buying an additional 7,632 shares during the period. UBS Asset Management Americas Inc. boosted its stake in shares of Progenics Pharmaceuticals by 41.2% in the first quarter. UBS Asset Management Americas Inc. now owns 38,724 shares of the biotechnology company’s stock worth $366,000 after buying an additional 11,300 shares during the period. Finally, BNP Paribas Arbitrage SA boosted its stake in shares of Progenics Pharmaceuticals by 1,077.2% in the first quarter. BNP Paribas Arbitrage SA now owns 12,961 shares of the biotechnology company’s stock worth $122,000 after buying an additional 11,860 shares during the period. 92.20% of the stock is currently owned by institutional investors and hedge funds.

Progenics Pharmaceuticals Inc. (PGNX) traded up 5.21% during trading on Tuesday, reaching $6.06. The company had a trading volume of 1,680,923 shares. The company has a market capitalization of $425.56 million, a PE ratio of 62.47 and a beta of 3.35. The firm’s 50 day moving average is $6.72 and its 200 day moving average is $8.29. Progenics Pharmaceuticals Inc. has a one year low of $4.84 and a one year high of $11.72.

COPYRIGHT VIOLATION WARNING: This piece of content was published by BBNS and is owned by of BBNS. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/progenics-pharmaceuticals-inc-nasdaqpgnx-position-lowered-by-fmr-llc-updated-updated-updated/1195089.html.

A number of analysts recently issued reports on the company. Zacks Investment Research raised Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, June 6th. Cantor Fitzgerald assumed coverage on Progenics Pharmaceuticals in a report on Wednesday, July 12th. They set an “overweight” rating and a $15.00 price objective on the stock. BidaskClub cut Progenics Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, July 11th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $12.00 price target on shares of Progenics Pharmaceuticals in a report on Thursday, June 8th. Finally, TheStreet cut Progenics Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 26th. Two analysts have rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Progenics Pharmaceuticals has a consensus rating of “Buy” and an average target price of $12.33.

About Progenics Pharmaceuticals

Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Despite Hitting Home Run, Judge Sets Longest Game Streak for Strikeouts
Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets


Leave a Reply

 
© 2006-2017 BBNS.